Pembrolizumab in Triple-Negative Breast Cancer. Reply
- PMID: 36239658
- DOI: 10.1056/NEJMc2210919
Pembrolizumab in Triple-Negative Breast Cancer. Reply
Comment on
-
Pembrolizumab in Triple-Negative Breast Cancer.N Engl J Med. 2022 Oct 13;387(15):1435. doi: 10.1056/NEJMc2210919. N Engl J Med. 2022. PMID: 36239656 No abstract available.
-
Pembrolizumab in Triple-Negative Breast Cancer.N Engl J Med. 2022 Oct 13;387(15):1435-1436. doi: 10.1056/NEJMc2210919. N Engl J Med. 2022. PMID: 36239657 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources